Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CEVEC Pharmaceuticals has received around EUR6m from NRW.BANK and Creathor Venture Fonds as well as from its current investors for strengthening CAP Technology platform based protein and vaccine commercialization business.
Subscribe to our email newsletter
The company is planning to develop some of its vaccines jointly with its partners from further financing round, which will be concluded by the end of 2011.
CAP Technology platform consists of CAP and CAP-T expression systems and is used for manufacturing therapeutic antibodies and complex biologics with human-like glycosylation and sialylation patterns.
CEVEC CCO Wolfgang Kintzel said after the successful launch of CAP und CAP-T in Europe, Asia/Pacific and the US for use in the field of protein and antibody expression, the new scientific data using the system for vaccine production open a new business opportunity for CEVEC.